Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunome Inc
(NQ:
IMNM
)
15.75
+0.78 (+5.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunome Inc
< Previous
1
2
3
Next >
Immunome (NASDAQ: IMNM) and Morphimmune Announce Merger to Develop Best-in-Class Targeted Cancer Therapies
June 29, 2023
Via
Spotlight Growth
Exposures
Product Safety
Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies
June 29, 2023
From
Immunome
Via
Business Wire
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity
May 23, 2023
From
Immunome, Inc.
Via
Business Wire
Immunome Reports First Quarter 2023 Financial Results
May 05, 2023
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results
March 16, 2023
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at 13th Annual World ADC London Conference
March 09, 2023
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
February 08, 2023
From
Immunome, Inc.
Via
Business Wire
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
January 06, 2023
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Immunome, Inc.
Via
Business Wire
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 09, 2022
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer
August 23, 2022
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Second Quarter 2022 Financial Results
August 05, 2022
From
Immunome, Inc.
Via
Business Wire
Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1
July 06, 2022
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
June 09, 2022
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at the Jefferies Healthcare Conference
June 02, 2022
From
Immunome, Inc.
Via
Business Wire
Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38
May 23, 2022
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant
May 19, 2022
From
Immunome, Inc.
Via
Business Wire
Immunome Reports First Quarter 2022 Financial Results
May 12, 2022
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Fourth Quarter and Full Year 2021 Financial Results
March 28, 2022
From
Immunome, Inc.
Via
Business Wire
Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing
February 08, 2022
From
Immunome, Inc.
Via
Business Wire
Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19
January 10, 2022
From
Immunome, Inc.
Via
Business Wire
Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald
December 07, 2021
From
Immunome, Inc.
Via
Business Wire
Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant
December 01, 2021
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
November 29, 2021
From
Immunome, Inc.
Via
Business Wire
Immunome Reports Third Quarter 2021 Financial Results
November 15, 2021
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at the Stifel Healthcare Conference
November 09, 2021
From
Immunome, Inc.
Via
Business Wire
Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis
October 20, 2021
From
Immunome, Inc.
Via
Business Wire
Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021
From
Immunome, Inc.
Via
Business Wire
Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021
From
Immunome, Inc.
Via
Business Wire
Immunome to Present at the Cantor Global Healthcare Conference
September 22, 2021
From
Immunome, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.